Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer

Journal of Orthopaedic Research

Volumn 30, Issue 4, 2012, Pages 662-672

  Urakawa, Hiroshi ^a   Nishida, Yoshihiro ^a   Knudson, Warren ^b   Knudson, Cheryl B ^b   Arai, Eisuke ^a   Kozawa, Eiji ^a   Futamura, Naohisa ^a   Wasa, Junji ^a   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

bone; breast cancer; hyaluronan; hyaluronan oligosaccharides; metastasis

Indexed keywords

ANTIMETASTATIC AGENT; HERMES ANTIGEN; HIGH MOLECULAR WEIGHT HYALURONIC ACID; HYALURONIC ACID; HYALURONIC ACID DECASACCHARIDE; HYALURONIC ACID DODECASACCHARIDE; HYALURONIC ACID HEXASACCHARIDE; HYALURONIC ACID OCTASACCHARIDE; HYALURONIC ACID OLIGOSACCHARIDE; HYALURONIC ACID TETRASACCHARIDE; MESSENGER RNA; OLIGOSACCHARIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE RADIOGRAPHY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; X RAY ANALYSIS;

ANIMALS; ANTIGENS, CD44; BONE NEOPLASMS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; OLIGOSACCHARIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TIBIA; VISCOSUPPLEMENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857033968     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21557     Document Type: Article

References (43)

1. Toole BP,. 1997. Hyaluronan in morphogenesis. J Intern Med 242: 35-40. (Pubitemid 27323863)
2. Ropponen K, Tammi M, Parkkinen J, et al. 1998. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342-347. (Pubitemid 28047077)
3. Auvinen P, Tammi R, Parkkinen J, et al. 2000. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156: 529-536. (Pubitemid 30643808)
4. Anttila MA, Tammi RH, Tammi MI, et al. 2000. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60: 150-155. (Pubitemid 30058745)
5. Kosaki R, Watanabe K, Yamaguchi Y,. 1999. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 59: 1141-1145. (Pubitemid 29135978)
6. Udabage L, Brownlee GR, Waltham M, et al. 2005. Anti sense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 65: 6139-6150. (Pubitemid 40994399)
7. Nishida Y, Knudson W, Knudson CB, et al. 2005. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 307: 194-203. (Pubitemid 40732745)
8. Udabage L, Brownlee GR, Nilsson SK, et al. 2005. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 310: 205-217. (Pubitemid 41393701)
9. Jiang D, Liang J, Noble PW,. 2007. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23: 435-461.
10. Hamilton SR, Fard SF, Paiwand FF, et al. 2007. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282: 16667-16680. (Pubitemid 47100370)
11. Jackson DG,. 2009. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 230: 216-231.
12. Toole B,. 2009. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 15: 7462-7468.
13. Russo RIC, Garcia MG, Alaniz L, et al. 2008. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 122: 1012-1018. (Pubitemid 351213998)
14. Ghatak S, Misra S, Toole BP,. 2002. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277: 38013-38020. (Pubitemid 35154652)
15. Engelman JA,. 2009. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
16. Vivanco I, Sawyers CL,. 2002. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. (Pubitemid 37328931)
17. Bourguignon LYW, Peyrollier K, Xia WL, et al. 2008. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651.
18. Bourguignon L, Wong G, Earle C, et al. 2010. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, MicroRNA-10b expression and RhoA/RhoC upregulation leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 285: 36721-36735.
19. Lesley J, Hascall VC, Tammi M, et al. 2000. Hyaluronan binding by cell surface CD44. J Biol Chem 275: 26967-26975.
20. Hosono K, Nishida Y, Knudson W, et al. 2007. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 171: 274-286. (Pubitemid 47339244)
21. Slomiany MG, Dai L, Tolliver LB, et al. 2009. Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary human ovarian carcinoma cells by small hyaluronan oligosaccharides. Clin Cancer Res 15: 7593-7601.
22. Coleman RE,. 1997. Skeletal complications of malignancy. Cancer 80: 1588-1594. (Pubitemid 27444031)
23. McQuay HJ, Collins SL, Carroll D, et al. 2000. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev C D001793.
24. Gnant M, Mlineritsch B, Schippinger W, et al. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691.
25. Stopeck AT, Lipton A, Body JJ, et al. 2010. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139.
26. Knudson W, Casey B, Nishida Y, et al. 2000. Hyaluronan oligosaccharides perturb cartilage matrix homeostasis and induce chondrocytic chondrolysis. Arthritis Rheum 43: 1165-1174. (Pubitemid 30368196)
27. Tawada A, Masa T, Oonuki Y, et al. 2002. Large-scale preparation, purification, and characterization of hyaluronan oligosaccharides from 4-mers to 52-mers. Glycobiology 12: 421-426.
28. Sheridan C, Kishimoto H, Fuchs RK, et al. 2006. CD44(+)/CD24(-) breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
29. Mulder JWR, Kruyt PM, Sewnath M, et al. 1994. Colorectal-cancer prognosis and expression of exon-V6-containing CD44 proteins. Lancet 344: 1470-1472. (Pubitemid 24351702)
30. Mayer B, Jauch KW, Gunthert U, et al. 1993. De-novo expression of CD44 and survival in gastric-cancer. Lancet 342: 1019-1022. (Pubitemid 23314804)
31. Gotte M, Yip GW,. 2006. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237. (Pubitemid 44799736)
32. Diaz LK, Zhou X, Wright ET, et al. 2005. C44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clinical Cancer Res 11: 3309-3314. (Pubitemid 40627880)
33. Friedrichs K, Franke F, Lisboa BW, et al. 1995. CD44 isoforms correlate with cellular-differentiation but not with prognosis in human breast-cancer. Cancer Res 55: 5424-5433.
34. Toole BP, Ghatak S, Misra S,. 2008. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 9: 249-252.
35. Alaniz L, García MG, Gallo-Rodriguez C, et al. 2006. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology 16: 359-367.
36. Zeng C, Toole BP, Kinney SD, et al. 1998. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77: 396-401. (Pubitemid 28299876)
37. Teriete P, Banerji S, Noble M, et al. 2004. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell 13: 483-496. (Pubitemid 38299377)
38. Underhill CB, Toole BP,. 1979. Binding of hyaluronate to the surface of cultured-cells. J Cell Biol 82: 475-484.
39. Tammi R, Rilla K, Pienimaki JP, et al. 2001. Hyaluronan enters keratinocytes by a novel endocytic route catabolism. J Biol Chem 276: 35111-35122.
40. Hua Q, Knudson CB, Knudson W,. 1993. Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J Cell Sci 106: 365-375. (Pubitemid 23286807)
41. Matou-Nasri S, Gaffney J, Kumar S, et al. 2009. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 35: 761-773.
42. Gao F, Liu YW, He YQ, et al. 2010. Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis. Matrix Biol 29: 107-116.
43. Rupp U, Schoendorf-Holland E, Eichbaum M, et al. 2007. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 18: 477-485. (Pubitemid 46712412)